Supriya Life Sciences Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
801.80 +97.65 (13.87%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
703.45
Today’s High
833.35
52 Week Low
240.1
52 Week High
833.35
806.85 +103.40 (14.70%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
704.5
Today’s High
833.4
52 Week Low
239.8
52 Week High
833.4
Key Metrics
- Market Cap (In Cr) 5661.56
- Beta -
- Div. Yield (%) 0.11
- P/B 6.94
- TTM P/E 28.81
- Peg Ratio -28.01
- Sector P/E 32.87
- D/E 0.01
- Open Price 703.45
- Prev Close 704.15
Supriya Life Sciences Analysis
Price Analysis
-
1 Week10.28%
-
3 Months28.54%
-
6 Month91.31%
-
YTD123.49%
-
1 Year179.37%
Risk Meter
- 51% Low risk
- 51% Moderate risk
- 51% Balanced Risk
- 51% High risk
- 51% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 0
- 0
- 0
- 0
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 2
- 2
- 2
- 2
Supriya Life Sciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 570.37
- Selling/ General/ Admin Expenses Total
- 67.64
- Depreciation/ Amortization
- 15.81
- Other Operating Expenses Total
- 108.02
- Total Operating Expense
- 413.21
- Operating Income
- 157.17
- Net Income Before Taxes
- 165.69
- Net Income
- 119.11
- Diluted Normalized EPS
- 14.8
- Period
- 2024
- Total Assets
- 921.24
- Total Liabilities
- 105.87
- Total Equity
- 815.37
- Tangible Book Valueper Share Common Eq
- 101.1
- Period
- 2024
- Cashfrom Operating Activities
- 113.31
- Cashfrom Investing Activities
- -173.58
- Cashfrom Financing Activities
- -22.36
- Net Changein Cash
- -82.63
- Period
- 2023
- Total Revenue
- 460.94
- Selling/ General/ Admin Expenses Total
- 114.77
- Depreciation/ Amortization
- 11.82
- Other Operating Expenses Total
- 2.29
- Total Operating Expense
- 343.77
- Operating Income
- 117.17
- Net Income Before Taxes
- 123.49
- Net Income
- 89.86
- Diluted Normalized EPS
- 11.78
- Period
- 2023
- Total Assets
- 820.28
- Total Liabilities
- 120.82
- Total Equity
- 699.46
- Tangible Book Valueper Share Common Eq
- 86.77
- Period
- 2023
- Cashfrom Operating Activities
- 66.19
- Cashfrom Investing Activities
- -133.14
- Cashfrom Financing Activities
- -3.37
- Net Changein Cash
- -70.33
- Period
- 2022
- Total Revenue
- 530.05
- Selling/ General/ Admin Expenses Total
- 97.72
- Depreciation/ Amortization
- 10.12
- Other Operating Expenses Total
- 2.79
- Total Operating Expense
- 325.71
- Operating Income
- 204.34
- Net Income Before Taxes
- 207.24
- Net Income
- 151.81
- Diluted Normalized EPS
- 18.83
- Period
- 2022
- Total Assets
- 734.76
- Total Liabilities
- 119.08
- Total Equity
- 615.69
- Tangible Book Valueper Share Common Eq
- 76.31
- Period
- 2022
- Cashfrom Operating Activities
- 48.8
- Cashfrom Investing Activities
- -59.82
- Cashfrom Financing Activities
- 149.65
- Net Changein Cash
- 138.63
- Period
- 2021
- Total Revenue
- 385.37
- Selling/ General/ Admin Expenses Total
- 75.22
- Depreciation/ Amortization
- 6.76
- Other Operating Expenses Total
- 1.57
- Total Operating Expense
- 224.72
- Operating Income
- 160.64
- Net Income Before Taxes
- 167.39
- Net Income
- 123.83
- Diluted Normalized EPS
- 15.39
- Period
- 2021
- Total Assets
- 445.47
- Total Liabilities
- 176.88
- Total Equity
- 268.58
- Tangible Book Valueper Share Common Eq
- 36.48
- Period
- 2021
- Cashfrom Operating Activities
- 75.89
- Cashfrom Investing Activities
- -46.8
- Cashfrom Financing Activities
- -14.52
- Net Changein Cash
- 14.57
- Period
- 2020
- Total Revenue
- 311.64
- Selling/ General/ Admin Expenses Total
- 62.3
- Depreciation/ Amortization
- 6.38
- Other Operating Expenses Total
- 0.98
- Total Operating Expense
- 219.19
- Operating Income
- 92.45
- Net Income Before Taxes
- 96.23
- Net Income
- 73.4
- Diluted Normalized EPS
- 9.12
- Period
- 2020
- Total Assets
- 336.43
- Total Liabilities
- 187.24
- Total Equity
- 149.19
- Tangible Book Valueper Share Common Eq
- 18.14
- Period
- 2020
- Cashfrom Operating Activities
- 116.06
- Cashfrom Investing Activities
- -24.52
- Cashfrom Financing Activities
- -29.23
- Net Changein Cash
- 62.31
- Period
- 2019
- Total Revenue
- 277.84
- Selling/ General/ Admin Expenses Total
- 53.07
- Depreciation/ Amortization
- 5.44
- Other Operating Expenses Total
- -0.01
- Total Operating Expense
- 215.92
- Operating Income
- 61.92
- Net Income Before Taxes
- 57.1
- Net Income
- 39.42
- Diluted Normalized EPS
- 4.71
- Period
- 2019
- Total Assets
- 253.05
- Total Liabilities
- 159.26
- Total Equity
- 93.79
- Tangible Book Valueper Share Common Eq
- 11.41
- Period
- 2019
- Cashfrom Operating Activities
- 48.67
- Cashfrom Investing Activities
- 4.83
- Cashfrom Financing Activities
- -49.71
- Net Changein Cash
- 3.79
- Period
- 2018
- Total Revenue
- 212.91
- Selling/ General/ Admin Expenses Total
- 46.63
- Depreciation/ Amortization
- 5.33
- Other Operating Expenses Total
- 0.21
- Total Operating Expense
- 195.42
- Operating Income
- 17.49
- Net Income Before Taxes
- 14.46
- Net Income
- 8.73
- Diluted Normalized EPS
- 1.08
- Period
- 2018
- Total Assets
- 245.39
- Total Liabilities
- 190.74
- Total Equity
- 54.66
- Tangible Book Valueper Share Common Eq
- 6.73
- Period
- 2018
- Cashfrom Operating Activities
- 27.76
- Cashfrom Investing Activities
- -4.71
- Cashfrom Financing Activities
- -20.01
- Net Changein Cash
- 3.03
- Period
- 2024-09-30
- Total Revenue
- 166.1
- Selling/ General/ Admin Expenses Total
- 19.68
- Depreciation/ Amortization
- 4.74
- Other Operating Expenses Total
- 35.72
- Total Operating Expense
- 106.13
- Operating Income
- 59.97
- Net Income Before Taxes
- 62.06
- Net Income
- 46.15
- Diluted Normalized EPS
- 5.71
- Period
- 2024-09-30
- Total Assets
- 1012.39
- Total Liabilities
- 106.5
- Total Equity
- 905.89
- Tangible Book Valueper Share Common Eq
- 112.22
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 92.16
- Cashfrom Investing Activities
- -82.53
- Cashfrom Financing Activities
- -0.27
- Net Changein Cash
- 9.36
- Period
- 2024-06-30
- Total Revenue
- 160.63
- Selling/ General/ Admin Expenses Total
- 20.08
- Depreciation/ Amortization
- 4.66
- Other Operating Expenses Total
- 29.4
- Total Operating Expense
- 102.74
- Operating Income
- 57.89
- Net Income Before Taxes
- 59.77
- Net Income
- 44.64
- Diluted Normalized EPS
- 5.54
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 158.18
- Selling/ General/ Admin Expenses Total
- 17.14
- Depreciation/ Amortization
- 3.91
- Other Operating Expenses Total
- 27.27
- Total Operating Expense
- 106.59
- Operating Income
- 51.59
- Net Income Before Taxes
- 53.18
- Net Income
- 36.93
- Diluted Normalized EPS
- 4.59
- Period
- 2024-03-31
- Total Assets
- 921.24
- Total Liabilities
- 105.87
- Total Equity
- 815.37
- Tangible Book Valueper Share Common Eq
- 101.1
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 113.31
- Cashfrom Investing Activities
- -173.58
- Cashfrom Financing Activities
- -22.36
- Net Changein Cash
- -82.63
- Period
- 2023-12-31
- Total Revenue
- 140.07
- Selling/ General/ Admin Expenses Total
- 17.56
- Depreciation/ Amortization
- 3.96
- Other Operating Expenses Total
- 26.4
- Total Operating Expense
- 102.54
- Operating Income
- 37.53
- Net Income Before Taxes
- 40.1
- Net Income
- 29.79
- Diluted Normalized EPS
- 3.7
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 140.1
- Selling/ General/ Admin Expenses Total
- 17.5
- Depreciation/ Amortization
- 3.98
- Other Operating Expenses Total
- 29.2
- Total Operating Expense
- 112.32
- Operating Income
- 27.77
- Net Income Before Taxes
- 29.78
- Net Income
- 23.88
- Diluted Normalized EPS
- 2.97
- Period
- 2023-09-30
- Total Assets
- 843.03
- Total Liabilities
- 89.86
- Total Equity
- 753.17
- Tangible Book Valueper Share Common Eq
- 93.42
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 55.97
- Cashfrom Investing Activities
- -80.03
- Cashfrom Financing Activities
- -17.71
- Net Changein Cash
- -41.78
- Period
- 2023-06-30
- Total Revenue
- 132.02
- Selling/ General/ Admin Expenses Total
- 15.43
- Depreciation/ Amortization
- 3.95
- Other Operating Expenses Total
- 24.88
- Total Operating Expense
- 91.49
- Operating Income
- 40.54
- Net Income Before Taxes
- 42.64
- Net Income
- 28.51
- Diluted Normalized EPS
- 3.54
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 142.27
- Selling/ General/ Admin Expenses Total
- 15.3
- Depreciation/ Amortization
- 3.01
- Other Operating Expenses Total
- 24.36
- Total Operating Expense
- 90.24
- Operating Income
- 52.04
- Net Income Before Taxes
- 53.29
- Net Income
- 38.23
- Diluted Normalized EPS
- 4.76
- Period
- 2023-03-31
- Total Assets
- 820.28
- Total Liabilities
- 120.82
- Total Equity
- 699.46
- Tangible Book Valueper Share Common Eq
- 86.77
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 66.19
- Cashfrom Investing Activities
- -133.14
- Cashfrom Financing Activities
- -3.37
- Net Changein Cash
- -70.33
- Period
- 2022-12-31
- Total Revenue
- 105.14
- Selling/ General/ Admin Expenses Total
- 14.64
- Depreciation/ Amortization
- 2.95
- Other Operating Expenses Total
- 25.1
- Total Operating Expense
- 94.05
- Operating Income
- 11.09
- Net Income Before Taxes
- 12.64
- Net Income
- 9.52
- Diluted Normalized EPS
- 1.18
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Supriya Life Sciences Technical
Moving Average
SMA
- 5 Day697.81
- 10 Day668.23
- 20 Day638.57
- 50 Day605.74
- 100 Day535.66
- 300 Day447.25
Supriya Life Sciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- FDC
- 488.25
- 4.2
- 0.87
- 659
- 375.65
- 7949.2
- Orchid Pharma
- 1450.05
- -22.95
- -1.56
- 1591.55
- 529.95
- 7354.52
- Supriya Life Sciences
- 801.8
- 97.65
- 13.87
- 833.35
- 240.1
- 6453.11
- Sequent Scientific
- 201.7
- 9.6
- 5
- 240.9
- 91.85
- 5032.03
- Hikal
- 390.75
- 3.1
- 0.8
- 416.15
- 260.65
- 4817.98
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- FDC
- 26.55
- 3.79
- 13.98
- 15.85
- Orchid Pharma
- 75.51
- 6.25
- -2.68
- -2.4
- Supriya Life Sciences
- 44.84
- 6.81
- 25.51
- 24.71
- Sequent Scientific
- -
- 7.41
- 1.41
- 1.18
- Hikal
- 69.74
- 4.08
- 10.69
- 5.86
Supriya Life Sciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-Oct-24
- Quarterly Results
- 10-Aug-24
- Quarterly Results
- 28-May-24
- Audited Results & Final Dividend
- 07-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 26-May-23
- Audited Results & Final Dividend
- 14-Feb-23
- Quarterly Results
- 10-Nov-22
- Quarterly Results
- 12-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 27-Sept-24
- 16-Sept-24
- AGM
- 30-Jul-24
- 26-Jun-24
- POM
- 29-Sept-23
- 06-Sept-23
- AGM
- 01-Aug-23
- 30-Jun-23
- POM
- 23-Apr-23
- 21-Mar-23
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 28-May-24
- -
- 20-Sept-24
- 0.8
- 26-May-23
- -
- 15-Sept-23
- 0.6
- 20-May-22
- -
- 01-Sept-22
- 0.6
